ELMD

• Record Financial Performance: The company reported its 15th consecutive quarter of year-over-year revenue and profit growth. Q4 net revenue reached a record $19.4 million (up 12%), with full-year fiscal 2026 revenue hitting $73.8 million (up 15.3%). Diluted EPS was a record $1.30 for the full year.

• Sales Force Expansion & Productivity: ElectroMed ended the quarter with 64 direct sales representatives, an increase of six from Q3. Revenue per weighted average rep exceeded targets at $1,145,000. The company is hiring ahead of planned territory expansions in fiscal 2027 to capitalize on the underserved bronchiectasis market.

• Strategic Focus on Bronchiectasis: Management highlighted that only 16% of the ~1 million diagnosed U.S. bronchiectasis patients are receiving High-Frequency Chest Wall Oscillation (HFCWO) therapy. Initiatives include the 'Triple Down on Bronchiectasis' campaign and 'Treat Smart from the Start' to educate clinicians and patients.

• Market Access & Payer Coverage: A key strategic win was adding 40 new payer contracts, expanding covered lives by over 6 million, bringing total coverage to 87% of U.S. lives. This reduces out-of-pocket burdens for patients.

• Technology & Regulatory Tailwinds: The 'Smart Order' ePrescribe solution processed >45% of orders in Q4, shipping five days faster than faxed orders. This positions ElectroMed well as CMS mandates the phase-out of faxes by May 2028.

• Leadership Transition: CEO Jim Cunniff announced his retirement, expected in April 2027. He expressed confidence in the succession plan and the current leadership team's ability to execute the growth strategy.

• Operational Efficiency: Gross margins remained strong at mid-70s percentage range. Operating income grew 43.7% year-over-year to $13.9 million for the full year, demonstrating significant operating leverage.

• Fiscal 2027 Revenue Per Rep: Management raised the target range for home care revenue per representative to $1,150,000 - $1,150,000 (Note: Transcript says '$1,050,000 to $1,150,000'). This is slightly below the FY26 actual of $1,145,000 but reflects a balance between high past productivity and ramp-up time for new hires.

• Top-Line Growth: Management reaffirmed expectations for double-digit top-line growth in fiscal 2027.

• Operating Leverage: Confirmed expectation to deliver expanded operating leverage, driven by leveraged benefits of revenue growth balanced against disciplined investment in operating expenses.

• Territory Expansion: Plan to fill 67 territories in fiscal 2027, including two new hospital account liaisons piloted in key markets.

ElectroMed operates primarily through two segments: Direct Home Care and Non-Home Care (Distributor and Hospital). For the full fiscal year 2026:

1. Direct Home Care Segment: Generated $66.6 million in revenue, representing a 16.3% year-over-year increase from $57.3 million. This segment accounted for approximately 90.3% of total net revenues ($73.8 million).
2. Non-Home Care Segment: Generated $7.2 million in revenue, representing a 6.7% year-over-year increase from prior year levels. This segment included Distributor revenue (up 12.7%) and Hospital revenue (up 9.6% annually, though down 29% in Q4 specifically). This segment accounted for approximately 9.7% of total net revenues.

Gross profit was $57.9 million, or 78.5% of net revenues, up from 78.1% in fiscal 2025.

• Hospital Sales Cycle Volatility: Hospital revenue is inherently less predictable due to longer sales cycles. In Q4, hospital revenue declined 29%, highlighting the risk of reliance on this channel for short-term consistency.

• Undiagnosed Market Size: While the opportunity is large (~4 million undiagnosed), there is a risk associated with the time and cost required to identify these patients and convert them to therapy.

• Regulatory Changes: Dependence on CMS rules regarding electronic signatures and order processing; failure to adapt could hinder adoption of the Smart Order system.

• Competitive Landscape: While no specific competitors were named, the management discussion implies the need to continuously innovate (R&D) and expand product lines to maintain competitive advantage and provide reps with complementary products.

Q: Analyst asked about capital allocation strategy given growing cash balances and strong stock price. / A: CFO stated priorities are de-risking, reinvesting in the business (sales force, marketing, R&D), and creating shareholder value via opportunistic share repurchases. They aim to support the added headcount while maintaining leveraged growth.

Q: Analyst inquired about the direction of R&D spend, specifically if it focuses on generator iteration, connectivity/data, or adjacent products. / A: CEO explained R&D is bifurcated into sustaining engineering for the existing Clearway generator and innovation. Key innovation areas are connectivity/smart nodes and expanding the vest line to include smaller sizes for better patient fit.

Q: Analyst asked for details on the acquisition pillar of their growth strategy, questioning if it aims for product diversification, capability acquisition, or data assets. / A: CEO indicated openness to any M&A that complements the sales rep's portfolio ('one plus one equals three') or leverages their strong reimbursement/contracting engine. No specific targets yet, but they look for synergies that enhance customer relationships or fill technology gaps.

Q: Analyst questioned payer mix trends, noting commercial payers decreased slightly while Medicare increased. Asked if this indicates a demographic shift or random fluctuation. / A: CEO noted the split has historically been 50/50. While demographics favor Medicare long-term, the primary driver recently is expanded payer coverage (adding 6M lives), which reduces out-of-network denials rather than shifting payer type significantly in the short term.

Q: Analyst asked how newly published CHESS guidelines impact detailing efforts and if they provide definitive treatment algorithms. / A: CEO clarified the guidelines are not definitive algorithms but support airway clearance as a key tool. He emphasized excitement over the concurrent launch of the BE Care Pathway by the NTM Foundation, which provides providers with a clearer toolbox for treating bronchiectasis, validating ElectroMed's therapy.